Home » Stocks » CYCC

Cyclacel Pharmaceuticals, Inc. (CYCC)

Stock Price: $3.20 USD -0.22 (-6.43%)
Updated Oct 30, 2020 3:01 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 15.56M
Revenue (ttm) 150,000
Net Income (ttm) -7.79M
Shares Out 4.86M
EPS (ttm) -4.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $3.20
Previous Close $3.42
Change ($) -0.22
Change (%) -6.43%
Day's Open 3.37
Day's Range 3.20 - 3.40
Day's Volume 39,024
52-Week Range 3.12 - 19.60

More Stats

Market Cap 15.56M
Enterprise Value n/a
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 4.86M
Float 4.82M
EPS (basic) -7.06
EPS (diluted) -4.85
FCF / Share -2.02
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 53,515
Short Ratio 0.19
Short % of Float 1.11%
Beta 1.10
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 103.76
PB Ratio 0.59
Revenue 150,000
Operating Income -10.04M
Net Income -7.79M
Free Cash Flow -7.78M
Net Cash 24.26M
Net Cash / Share 4.99
Gross Margin -3,105.33%
Operating Margin -6,692.00%
Profit Margin n/a
FCF Margin -5,188.67%
ROA -25.80%
ROE -35.88%
ROIC -286.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.33*
(566.56% upside)
Low
18.0
Current: $3.20
High
24.0
Target: 21.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-0.15-0.841.941.731.080.07-0.11
Revenue Growth----56.64%12.11%59.96%1471.01%---
Gross Profit-0.15-0.841.941.731.080.07-0.11
Operating Income-9.68-9.55-9.49-14.15-16.17-22.44-17.97-15.10-15.75-15.14
Net Income-7.83-7.29-7.47-11.79-14.34-19.39-10.15-13.19-15.24-16.02
Shares Outstanding0.820.600.380.170.140.090.060.030.030.02
Earnings Per Share-9.80-12.40-39.00-70.00-107.20-213.61-307.21-403.22-532.82-873.64
Operating Cash Flow-9.45-6.70-7.48-10.08-14.46-18.70-18.20-12.04-13.98-16.04
Capital Expenditures0.03-0.04-0.010.01-0.03-0.31-0.210.05-0.03
Free Cash Flow-9.42-6.74-7.49-10.07-14.49-19.01-18.41-11.99-13.98-16.01
Cash & Equivalents11.8917.5023.9116.5220.4424.1931.1516.4124.4529.50
Total Debt1.19---------
Net Cash / Debt10.6917.5023.9116.5220.4424.1931.1516.4124.4529.50
Assets15.3119.8226.0019.6624.7629.3935.5219.3526.0031.46
Liabilities3.614.554.245.395.937.707.509.346.506.54
Book Value11.7015.2721.7714.2718.8421.6928.0210.0219.5024.92
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cyclacel Pharmaceuticals, Inc.
Country United States
Employees 12
CEO Spiro Rombotis

Stock Information

Ticker Symbol CYCC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CYCC

Description

Cyclacel Pharmaceuticals, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.